{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:19:11Z","timestamp":1768000751579,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgrounds<\/jats:title>\n                <jats:p>Optimal concentration of ustekinumab (UST) predicting endoscopic remission has not been fully investigated in Crohn\u2019s disease (CD). We aimed to identify the optimal UST trough levels predicting clinical, laboratory and endoscopic remission in CD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-eight patients with CD were enrolled and investigated (27 patients by enteroscopy and 1 by colonoscopy). The endoscopic activity was assessed using the scoring system that applied the Rutgeerts score to observed intestine. Serum UST trough levels and anti-UST antibodies (AUAs) levels were determined by in-house immunoassays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Endoscopic activity was negatively correlated with serum UST trough levels (Spearman\u2019s rank correlation coefficient (\u03c1)\u2009=\u2009\u2212\u20090.66, <jats:italic>P<\/jats:italic>\u2009=\u20090.0001) and serum albumin levels (\u03c1\u2009=\u2009\u2212\u20090.60, <jats:italic>P<\/jats:italic>\u2009=\u20090.0007). The endoscopic activity was positively and significantly correlated with CRP (\u03c1\u2009=\u20090.59, <jats:italic>P<\/jats:italic>\u2009=\u20090.0009) and ESR (\u03c1\u2009=\u20090.44, <jats:italic>P<\/jats:italic>\u2009=\u20090.033). There was no significant association between the endoscopic score and AUA levels and\/or Crohn\u2019s disease activity index (CDAI). Serum UST trough levels and albumin levels were significantly higher in the endoscopic remission group (scores of 0 and 1) than in the non-endoscopic remission group (UST trough, mean 3.3 vs. 1.8\u00a0\u03bcg\/mL). No significant difference was observed in AUAs between the endoscopic remission and non-remission groups. Receiver operation curve (ROC) analysis revealed that the optimal cutoff value of UST trough levels predicting normal CRP and serum albumin levels was 1.7\u00a0\u03bcg\/mL for each, and the optimal cutoff value predicting endoscopic remission was 2.0\u00a0\u03bcg\/mL (AUC: 0.80, 95% CI 0.64\u20130.96).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Achievement of endoscopic remission requires higher UST trough levels than required for normalization of CRP and serum albumin levels.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02271-4","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T14:03:43Z","timestamp":1650549823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn\u2019s disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Hisashi","family":"Hirayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Bamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Inatomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Andoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"issue":"9853","key":"2271_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605.","journal-title":"Lancet"},{"key":"2271_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"A Kaser","year":"2010","unstructured":"Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573\u2013621.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2271_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn\u2019s disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289\u201397.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2271_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489\u2013526.","journal-title":"J Gastroenterol"},{"issue":"10","key":"2271_CR5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","volume":"45","author":"A Cholapranee","year":"2017","unstructured":"Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291\u2013302.","journal-title":"Aliment Pharmacol Ther"},{"key":"2271_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","volume":"202","author":"CL Langrish","year":"2004","unstructured":"Langrish CL, McKenzie BS, Wilson NJ, de Waal MR, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202:96\u2013105.","journal-title":"Immunol Rev"},{"key":"2271_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","volume":"45","author":"MF Neurath","year":"2019","unstructured":"Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 2019;45:1\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"2271_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmb.2010.07.046","volume":"402","author":"J Luo","year":"2010","unstructured":"Luo J, Wu SJ, Lacy ER, Orlovsky Y, Baker A, Teplyakov A, Obmolova G, Heavner GA, Richter HT, Benson J. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402(5):797\u2013812.","journal-title":"J Mol Biol"},{"issue":"4","key":"2271_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn\u2019s Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135(4):1130\u201341.","journal-title":"Gastroenterology"},{"issue":"16","key":"2271_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367(16):1519\u201328.","journal-title":"N Engl J Med"},{"issue":"20","key":"2271_CR11","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"key":"2271_CR12","first-page":"CD007572","volume":"11","author":"JK MacDonald","year":"2016","unstructured":"MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016;11:CD007572.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2271_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","volume":"14","author":"SB Hanauer","year":"2019","unstructured":"Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease. J Crohns Colitis. 2019;14(1):23\u201332.","journal-title":"J Crohns Colitis"},{"issue":"13","key":"2271_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"3","key":"2271_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2021;20(3):578\u201390.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2271_CR16","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/ibd\/izy134","volume":"24","author":"S Restellini","year":"2018","unstructured":"Restellini S, Khanna R, Afif W. Therapeutic drug monitoring with ustekinumab and vedolizumab in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(10):2165\u201372.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2271_CR17","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","volume":"154","author":"OJ Adedokun","year":"2018","unstructured":"Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn\u2019s disease. Gastroenterology. 2018;154(6):1660\u201371.","journal-title":"Gastroenterology"},{"issue":"9","key":"2271_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1655\u201368.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2271_CR19","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1016\/j.cgh.2019.02.042","volume":"17","author":"N Soufflet","year":"2019","unstructured":"Soufflet N, Boschetti G, Roblin X, Cuercq C, Williet N, Charlois AL, Duclaux-Loras R, Danion P, Mialon A, Faure M, et al. Concentrations of ustekinumab during induction therapy associate with remission in patients. Clin Gastroenterol Hepatol. 2019;17(12):2610\u20132.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2271_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","volume":"15","author":"R Battat","year":"2017","unstructured":"Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients. Clin Gastroenterol Hepatol. 2017;15(9):1427\u201334.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2271_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjz008","volume":"13","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernolle G, Van Assche G, Gils A, Vermeire S, et al. Ustekinumab exposure-outcome analysis in Crohn\u2019s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13(7):864\u201372.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2271_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","volume":"155","author":"P Rutgeerts","year":"2018","unstructured":"Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease. Gastroenterology. 2018;155(4):1045\u201358.","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"2271_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0016-5085(79)90384-6","volume":"77","author":"WR Best","year":"1979","unstructured":"Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn\u2019s Disease Activity Index (CDAI). Gastroenterology. 1979;77(4 Pt 2):843\u20136.","journal-title":"Gastroenterology"},{"issue":"4","key":"2271_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00535-013-0829-7","volume":"49","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn\u2019s disease under scheduled maintenance treatment. J Gastroenterol. 2014;49(4):674\u201382.","journal-title":"J Gastroenterol"},{"issue":"4","key":"2271_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","volume":"99","author":"P Rutgeerts","year":"1990","unstructured":"Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn\u2019s disease. Gastroenterology. 1990;99(4):956\u201363.","journal-title":"Gastroenterology"},{"issue":"7","key":"2271_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jgh.14962","volume":"35","author":"Y Morita","year":"2020","unstructured":"Morita Y, Imai T, Bamba S, Takahashi K, Inatomi O, Miyazaki T, Watanabe K, Nakamura S, Yoshida A, Endo Y, et al. Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn\u2019s disease. J Gastroenterol Hepatol. 2020;35(7):1163\u201370.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2271_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gut.30.7.983","volume":"30","author":"JY Mary","year":"1989","unstructured":"Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn\u2019s disease: a prospective multicentre study. Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983\u20139.","journal-title":"Gut"},{"issue":"4","key":"2271_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505\u201312.","journal-title":"Gastrointest Endosc"},{"issue":"16","key":"2271_CR29","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3748\/wjg.v27.i16.1828","volume":"27","author":"M State","year":"2021","unstructured":"State M, Negreanu L, Voiosu T, Voiosu A, Balanescu P, Mateescu RB. Surrogate markers of mucosal healing in inflammatory bowel disease: a systematic review. World J Gastroenterol. 2021;27(16):1828\u201340.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"2271_CR30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/apt.16551","volume":"54","author":"K Takenaka","year":"2021","unstructured":"Takenaka K, Kawamoto A, Hibiya S, Suzuki K, Fujii T, Motobayashi M, Shimizu H, Nagahori M, Saito E, Okamoto R, et al. Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn\u2019s disease. Aliment Pharmacol Ther. 2021;54(8):1052\u201360.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2271_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/j.gastro.2020.12.052","volume":"161","author":"S Soffer","year":"2021","unstructured":"Soffer S, Kopylov U, Klang E. Artificial intelligence for the evaluation of mucosal healing in IBD: the future is here. Gastroenterology. 2021;161(3):1073\u20134.","journal-title":"Gastroenterology"},{"issue":"6","key":"2271_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/jcm10061242","volume":"10","author":"S Restellini","year":"2021","unstructured":"Restellini S, Afif W. Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease. J Clin Med. 2021;10(6):1242.","journal-title":"J Clin Med"},{"key":"2271_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.028","author":"RS Dalal","year":"2021","unstructured":"Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR. Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study. Clin Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.028.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02271-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02271-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02271-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T01:04:51Z","timestamp":1650589491000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02271-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02271-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review boards of the Shiga University of Medical Science (permission No. R2017-136). All patients gave their written informed consent prior to their inclusion in this study. All methods were carried out in accordance with relevant guidelines and regulations. The registration number of the University Hospital Medical Information Network Center (UMIN) was 000033552.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA received the lecture fees from Janssen, Takeda, AbbVie, Tanabe-Mitsubishi. All other authors declare that they have no conflict of interest in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}